These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 27805571

  • 21. Peramivir clearance in continuous renal replacement therapy.
    Thomas B, Hollister AS, Muczynski KA.
    Hemodial Int; 2010 Jul; 14(3):339-40. PubMed ID: 20491974
    [No Abstract] [Full Text] [Related]

  • 22. [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
    Reina J.
    Rev Esp Quimioter; 2006 Dec; 19(4):317-22. PubMed ID: 17235399
    [No Abstract] [Full Text] [Related]

  • 23. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.
    Atiee G, Lasseter K, Baughman S, McCullough A, Collis P, Hollister A, Hernandez J.
    J Clin Pharmacol; 2012 Sep; 52(9):1410-9. PubMed ID: 21960669
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of a single intravenous dose of the neuraminidase inhibitor peramivir in the treatment of equine influenza.
    Yamanaka T, Bannai H, Nemoto M, Tsujimura K, Kondo T, Muranaka M, Hobo S, Minamijima YH, Yamada M, Matsumura T.
    Vet J; 2012 Aug; 193(2):358-62. PubMed ID: 22326934
    [Abstract] [Full Text] [Related]

  • 25. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.
    Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J, S-021812 Clinical Study Group.
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5267-76. PubMed ID: 21825298
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors.
    Komeda T, Ishii S, Itoh Y, Sanekata M, Yoshikawa T, Shimada J.
    J Infect Chemother; 2016 Oct; 22(10):677-84. PubMed ID: 27497712
    [Abstract] [Full Text] [Related]

  • 30. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
    Kakuda TN, Yogaratnam J, Rito J, Boyce M, Mitchell T, Gupta K, Symons JA, Chanda S, Van Remoortere P, Fry J.
    Antivir Ther; 2018 Oct; 23(7):555-566. PubMed ID: 29927386
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Quantification of peramivir (a novel anti-influenza drug) in human plasma by hydrophilic interaction chromatography/tandem mass spectrometry.
    Li Y, Zhang X, Wang X, Li S, Ruan J, Zhang Z.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr 01; 877(10):933-8. PubMed ID: 19285926
    [Abstract] [Full Text] [Related]

  • 33. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation.
    Komeda T, Ishii S, Itoh Y, Ariyasu Y, Sanekata M, Yoshikawa T, Shimada J.
    J Infect Chemother; 2015 Mar 01; 21(3):194-201. PubMed ID: 25523716
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.
    Biochem Biophys Res Commun; 2012 Dec 07; 429(1-2):51-6. PubMed ID: 23131559
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series.
    Cies JJ, Moore WS, Enache A, Chopra A.
    Pharmacotherapy; 2019 Nov 07; 39(11):1060-1065. PubMed ID: 31514223
    [Abstract] [Full Text] [Related]

  • 40. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.
    Sidwell RW, Smee DF.
    Expert Opin Investig Drugs; 2002 Jun 07; 11(6):859-69. PubMed ID: 12036429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.